🇺🇸 FDA
Pipeline program

sunitinib or pazopanib

MRCC-China collaboration

Unknown small_molecule active

Quick answer

sunitinib or pazopanib for Metastatic Renal Cell Carcinoma is a Unknown program (small_molecule) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Metastatic Renal Cell Carcinoma
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials